Literature DB >> 22752785

Role of mammalian target of rapamycin in hypoxic or ischemic brain injury: potential neuroprotection and limitations.

Hongju Chen1, Yi Qu, Binzhi Tang, Tao Xiong, Dezhi Mu.   

Abstract

Hypoxic or ischemic stress causes serious brain injury via various pathologic mechanisms including suppressed protein synthesis, neuronal apoptosis, and the release of neurotoxic substances. Many neuroprotective treatments of hypoxic or ischemic brain injury rely on these pathologic mechanisms. The mammalian target of rapamycin (mTOR), an atypical Ser/Thr protein kinase, could be a novel therapeutic target. mTOR plays a critical role in regulating many activities such as protein synthesis, cell growth, and cell death. Furthermore, mTOR could promote angiogenesis, neuronal regeneration, and synaptic plasticity, reduce neuronal apoptosis, and remove neurotoxic substances, which are all closely associated with the repair and survival mechanisms of hypoxic or ischemic brain injury. Although there is currently controversy with regard to regulating the activation of mTOR, the effective neuroprotective functions resulting from mTOR activation have been confirmed by various studies. Considering the potential capability for mTOR in regulating the repair and survival mechanisms of hypoxic or ischemic brain injury, mTOR may be a novel target for neuroprotective treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22752785     DOI: 10.1515/revneuro-2012-0001

Source DB:  PubMed          Journal:  Rev Neurosci        ISSN: 0334-1763            Impact factor:   4.353


  20 in total

1.  The Synergistic Combination of Everolimus and Paroxetine Exerts Post-ischemic Neuroprotection In Vitro.

Authors:  V S Suvanish Kumar; Etheresia Pretorius; G K Rajanikant
Journal:  Cell Mol Neurobiol       Date:  2018-07-30       Impact factor: 5.046

Review 2.  Remote neurodegeneration: multiple actors for one play.

Authors:  Maria Teresa Viscomi; Marco Molinari
Journal:  Mol Neurobiol       Date:  2014-01-19       Impact factor: 5.590

3.  Neuroprotective effect of vildagliptin against cerebral ischemia in rats.

Authors:  Salma A El-Marasy; Rehab F Abdel-Rahman; Reham M Abd-Elsalam
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-07-18       Impact factor: 3.000

4.  α-Endosulfine (ARPP-19e) Expression in a Rat Model of Stroke.

Authors:  Rupal I Mehta; Natalia Tsymbalyuk; Svetlana Ivanova; Jesse A Stokum; Kyoon Woo; Volodymyr Gerzanich; J M Simard
Journal:  J Neuropathol Exp Neurol       Date:  2017-10-01       Impact factor: 3.685

5.  Squamosamide derivative FLZ protected tyrosine hydroxylase function in a chronic MPTP/probenecid mouse model of Parkinson's disease.

Authors:  Xiu-Qi Bao; Liang-Yu Wu; Xiao-Liang Wang; Hua Sun; Dan Zhang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-02-13       Impact factor: 3.000

6.  The mechanistic target of rapamycin (mTOR) pathway and S6 Kinase mediate diazoxide preconditioning in primary rat cortical neurons.

Authors:  Somhrita Dutta; Ibolya Rutkai; Prasad V G Katakam; David W Busija
Journal:  J Neurochem       Date:  2015-07-01       Impact factor: 5.372

7.  Effects of rapamycin on cerebral oxygen supply and consumption during reperfusion after cerebral ischemia.

Authors:  O Z Chi; S Barsoum; N M Vega-Cotto; E Jacinto; X Liu; S J Mellender; H R Weiss
Journal:  Neuroscience       Date:  2015-12-29       Impact factor: 3.590

8.  Pyruvate minimizes rtPA toxicity from in vitro oxygen-glucose deprivation and reoxygenation.

Authors:  Myoung-Gwi Ryou; Gourav Roy Choudhury; Ali Winters; Luokun Xie; Robert T Mallet; Shao-Hua Yang
Journal:  Brain Res       Date:  2013-07-23       Impact factor: 3.252

9.  Mammalian target of rapamycin cell signaling pathway contributes to the protective effects of ischemic postconditioning against stroke.

Authors:  Rong Xie; Peng Wang; Michelle Cheng; Robert Sapolsky; Xunming Ji; Heng Zhao
Journal:  Stroke       Date:  2014-07-10       Impact factor: 7.914

10.  Alterations of irisin, adropin, preptin and BDNF concentrations in coronary heart disease patients comorbid with depression.

Authors:  Wenxiu Han; Chunxiang Zhang; Hui Wang; Mengqi Yang; Yujin Guo; Gongying Li; Hailiang Zhang; Changshui Wang; Dan Chen; Chunmei Geng; Pei Jiang
Journal:  Ann Transl Med       Date:  2019-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.